Diabetes: A major co-morbidity of cystic fibrosis

Diabetes and Metabolism

Volumn 31, Issue 3 I, 2005, Pages 221-232

  Costa, M ^a   Potvin, S ^a   Berthiaume, Y ^a   Gauthier, L ^a   Jeanneret, A ^a   Lavoie, A ^a   Levesque, R ^a   Chiasson, J L ^a   Rabasa Lhoret, R ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cystic fibrosis; Diabetes; Insulin therapy

Indexed keywords

ACARBOSE; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; GLIBENCLAMIDE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; MUCOLYTIC AGENT; PANCREAS ENZYME; PIOGLITAZONE; REPAGLINIDE; RETINOL; ROSIGLITAZONE; TOLBUTAMIDE; VITAMIN D; VITAMIN K GROUP;

ADOLESCENT; ADULT; AGE; CLINICAL FEATURE; COMORBIDITY; CYSTIC FIBROSIS; DETERIORATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LIFE EXPECTANCY; LIVER TOXICITY; LUNG INFECTION; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRESCHOOL CHILD; PREVALENCE; REVIEW; SCHOOL CHILD; SCREENING; WEIGHT REDUCTION;

EID: 21844439234     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70189-1     Document Type: Review

References (97)

1. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr, 1988, 112, 373-7.
2. Moran A, Hardin D, Rodman D,et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract, 1999, 45, 61-73.
3. Ratjen F, Doring G. Cystic fibrosis. Lancet, 2003, 361, 681-9.
4. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr, 1991, 118, 715-23.
5. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax, 1991, 46, 881-885.
6. Riggs AC, Seaquist ER, Moran A. Guidelines for the diagnosis and therapy of diabetes mellitus in cystic fibrosis. Curr Opin Pulm Med, 1999, 5, 378-82.
7. Hardin DS, Moran A. Diabetes mellitus in cystic fibrosis. Endocrinol Metab Clin North Am, 1999, 28, 787-800.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2004, 27 (Suppl 1), S5-S10.
9. Belli D, Debray D, Logeais AG, et al. Prise en charge du patient atteint de mucoviscidose - Observance, nutrition, gastro-ente"rologic et me"tabolisme, http://www.anaes.fr/accessed march 1rst 2005. 3-1-2005.
10. Canadian Diabetes Association. Definition, classification and diagnosis of diabetes and other dysglycemic categories. Canadian J Diabetes, 2003, 27 suppl 2, s7-s9.
11. UK cystic fibrosis trust diabetes working group. Management of cystic fibrosis related diabetes mellitus. Cystic fibrosis Trust. 2004. Bromley, Kent UK, Cystic fibrosis Trust. 6-1-0040.
12. Solomon MP, Wilson DC, Corey M, et al. Glucose intolerance in children with cystic fibrosis. J Pediatr, 2003, 142, 128-32.
13. Moran A. Diagnosis, screening and management of cystic fibrosis-related diabetes. Current Diab Rep, 2002, 2, 111-5.
14. Mackie AD, Thronton SD, Edenborough FP. Cystic fibrosis-related diabetes. Diabet Med, 2003, 20, 425-36.
15. Hardin DS. The diagnosis and management of cystic fibrosis related diabetes. 1998.
16. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. B Med J, 1995, 311, 655-9.
17. Hardin, D S, Cohen, RM, Clark J, Kriz D, Spears S. Medical and nutritional management of cystic fibrosis related diabetes. 1-51. 2002. New Orlean, Lousiana, Cystic fibrosis Foundation. 10-3-0020.
18. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr, 1994, 83, 849-53.
19. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr, 1998, 133, 10-7.
20. Lombarde F, De Luca F, Rosano M, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol, 2003, 149, 53-9.
21. Hinds A, Sheehan AG, Machida H, Parsons HG. Postprandial hyperglycemia and pancreatic function in cystic fibrosis patients. Diabetes Res, 1991, 18, 69-78.
22. Cucinotta D, De Luca F, Scoglio R, et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr, 1999, 88, 389-93.
23. The Cystic Fibrosis Genotype-Phenotype Consortium Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med, 1993, 329, 1308-13.
24. Lanng S, Thorsteinsson B, Erichsen G, Nerup J, Koch C. Glucose tolerance in cystic fibrosis. Arch Dis Child, 1991, 66, 612-6.
25. Cotellessa M, Minicucci L, Diana M.C, et al. Phenotype/genotype correlation and cystic fibrosis related diabetes mellitus (Italian Multicenter Study). J Pediatr Endocrinol Metab, 2000, 13, 1087-93.
26. Braun J, Arnemann J, Lohrey M, et al. No association between the deltaF508 cystic fibrosis mutation and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes, 1999, 107, 568-9.
27. Castellani C, Quinzii C, Altieri S, Mastella G, Assael BM. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet Test, 2001, 5, 249-54.
28. Stutchfield PR, O'Halloran SM, Smith CS, Woodrow JC, Bottazzo GF, Heaf D. HLA type, islet cell antibodies, and glucose intolerance in cystic fibrosis. Arch Dis Child, 1988, 63, 1234-9.
29. Lanng S, Thorsteinsson B, Pociot F, et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr, 1993, 82, 150-4.
30. Hardin DS, LeBlanc A, Lukenbaugh S, Para L, Seilheimer DK. Proteolysis associated with insulin resistance in cystic fibrosis. Pediatrics, 1998, 101, 433-7.
31. Moran A, Milla C, Ducret R, Nair KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. Diabetes, 2001, 50, 1336-43.
32. Holt TL, Ward LC, Francis PJ, Isles A, Cooksley WG, Shepherd RW. Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease. Am J Clin Nutr, 1985, 41, 1061-6.
33. Ward SA, Tomezsko JL, Holsclaw DS, Paolone AM. Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. Am J Clin Nutr, 1999, 69, 913-9.
34. Sandier M. Is the lung a 'target organ' in diabetes mellitus? Arch Intern Med, 1990, 150, 1385-8.
35. Niranjan V, McBrayer DG, Ramirez LC, Raskin P, Hsia CC. Glycemic control and cardiopulmonary function in patients with insulin-dependent diabetes mellitus. Am J Med, 1997, 103, 504-13.
36. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care, 2004, 27, 752-7.
37. Cystic fibrosis Foundation. Cystic fibrosis foundation. Patient registry. Annual data report 2001. Cystic fibrosis Foundation. 1-12. 2002. Bethesda, Maryland.
38. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr, 1992, 151, 684-7.
39. Cucinotta D, Arrigo T, De Luca F, et al. Metabolic and clinical events preceding diabetes mellitus onset in cystic fibrosis. Eur J Endocrinol, 1996, 134, 731-6.
40. Koch C, Rainisio M, Madessani U, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol, 2001, 32, 343-50.
41. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med, 2000, 162, 891-5.
42. Schaedel C de M I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol, 2002, 33, 483-91.
43. Reisman J, Corey M, Canny G, Levison H. Diabetes mellitus in patients with cystic fibrosis: effect on survival. Pediatrics, 1990, 86, 374-7.
44. Rolon MA, Benali K, Munck A, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr, 2001, 90, 860-7.
45. Dobson L, Sheldon CD, Hattersley AT. Understanding cystic-fibrosis- related diabetes: best thought of as insulin deficiency? J R Soc Med, 2004, 97 (Suppl 44), 26-35.
46. Dolan TF, Jr. Microangiopathy in a young adult with cystic fibrosis and diabetes mellitus. N Engl J Med, 1986, 314, 991-2.
47. Yung B, Landers A, Mathalone B, Gyi KM, Hodson ME. Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes. Respir Med, 1998, 92, 871-2.
48. Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiotz PO, Koch C. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr, 1994, 83, 72-7.
49. Sullivan MM, Denning CR. Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics, 1989, 84, 642-7.
50. Oppenheimer EH. Glomerular lesions in cystic fibrosis: possible relation to diabetes mellitus, acquired cyanotic heart disease and cirrhosis of the liver. Johns Hopkins Med J, 1972, 131, 351-36.
51. Allen JL. Progressive nephropathy in a patient with cystic fibrosis and diabetes. N Engl J Med, 1986, 315, 764.
52. Spaide RF, Diamond G, D'Amico RA, Gaerlan PF, Bisberg DS. Ocular findings in cystic fibrosis. Am J Ophthalmol, 1987, 103, 204-10.
53. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med, 1995, 332, 848-54.
54. Schlesinger DM, Holsclw DS, Fyfe B. Generalized atherosclerosis in a adult with cystic fibrosis and diabetes mellitus. Pediatr Pulmonol, 1997, Suppl. 14, 366A.
55. Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic fibrosis. Am J Clin Nutr, 2002, 75, 1005-11.
56. Abdul-Karim FW, Dahms BB, Velasco ME, Rodman HM. Islets of Langerhans in adolescents and adults with cystic fibrosis. A quantitative study. Arch Pathol Lab Med, 1986, 110, 602-6.
57. Robert JJ, Mosnier-Pudar H. Diagnosis and treatment of diabetes in adult patients with cystic fibrosis. Rev Mal Respir, 2000, 17, 798-801.
58. Lohr M, Goertchen P, Nizze H, et al. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study. Virchows Arch A Pathol Anat Histopathol, 1989, 414, 179-85.
59. Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol 1984, 15, 278-84.
60. Soejima K, Landing BH. Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometnc and immunocytologic studies. Pediatr Pathol, 1986, 6, 25-46.
61. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab, 1996, 81, 1267-72.
62. Van Haren EH, Hopman WP, Rosenbusch G, Jansen JB, Van Herwaarden CL. Pancreatic morphology and function in adult patients with cystic fibrosis. Scand J Gastroenterol, 1992, 27, 695-8.
63. Wilmshurst EG, Soeldner JS, Holsclaw DS, et al. Endogenous and exogenous insulin responses in patients with cystic fibrosis. Pediatrics, 1975, 55, 75-82.
64. Hamdi I, Green M, Shneerson JM, Palmer CR, Hales CN. Proinsulin, proinsulin intermediate and insulin in cystic fibrosis. Clin Endocrinol (Oxf), 1993, 39, 21-6.
65. Lanng S, Thorsteinsson B, Roder ME, et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh), 1993, 128, 207-14.
66. Holl RW, Heinze E, Wolf A, Rank M, Teller WM. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur J Pediatr, 1995, 154, 356-61.
67. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child, 2002, 87, 430-1.
68. Larsen S, Hilsted J, Tronier B, Worning H. Pancreatic hormone secretion in chronic pancreatitis without residual beta-cell function. Acta Endocrinol (Copenh), 1988, 118, 357-64.
69. Hanna A. Le diabète associé à la fibrose kystique. Endocrinol Conf Scient, 2003, 3, 1-5.
70. Mohan V, Alagappan V, Snehalatha C, Ramachandran A, Thiruvengadam KV, Viswanathan M. Insulin and C-peptide responses to glucose load in cystic fibrosis. Diabete Metab, 1985, 11, 376-9.
71. Hardin D.S, LeBlanc A, Lukenbaugh S, Seilheimer DK. Insulin resistance is associated with decrease clinical status in cystic fibrosis. J Pediatr, 1997, 130, 948-56.
72. Hardin DS, LeBlanc A, Para L, Seilheimer DK. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes, 1999, 48, 1082-7.
73. Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes, 1994, 43, 1020-6.
74. Ahmad T, Nelson R, Taylor R. Insulin sensitivity and metabolic clearance rate of insulin in cystic fibrosis. Metabolism, 1994, 43, 163-7.
75. Lanng S, Thorsteinsson B, Roder ME, Nerup J, Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol (Oxf), 1994, 41, 217-23.
76. Cucinotta D, De Luca F, Gigante A, et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. Eur J Endocrinol, 1994, 130, 253-8.
77. Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab, 1994, 79, 80-5.
78. Hardin DS, LeBlanc A, Marshall G, Seilheimer DK. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab, 2001, 281, E1022-E1028.
79. Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria. Thorax, 1999, 54, 40-3.
80. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med, 2004, 21, 691-6.
81. Allen HF, Gay EC, Klingensmith GJ, Hamman RF. Identification and treatment of cystic fibrosis-related diabetes. A survey of current medical practice in the U.S. Diabetes Care, 1998, 21, 943-8.
82. Moran A, Milla C. Abnormal glucose tolerance in cystic fibrosis: why should patients be screened? J Pediatr, 2003, 142, 97-9.
83. Yung B, Kemp M, Hooper J, Hodson M. Random blood glucose alone in the diagnosis of cystic fibrosis related diabetes. Lancet, 1997, 349, 619.
84. Zemel BS, Kawchak DA, Cnaan A, Zhao H, Scanlin TF, Stallings VA. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis. Pediatr Res, 1996, 40, 578-86.
85. Allen JR, McCauley JC, Selby AM, et al. Differences in resting energy expenditure between male and female children with cystic fibrosis. J Pediatr, 2003, 142, 15-9.
86. Stallmgs VA. Gender, death and cystic fibrosis: is energy expenditure a component? J Pediatr, 2003, 142, 4-6.
87. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest, 2004, 125, 1S-39S.
88. Rabasa-Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Diabetes Care, 1999, 22, 667-73.
89. Rosenecker J, Eichler I, Barmeier H, von der HH. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose- lowering agents. Pediatr Pulmonol, 2001, 32, 351-5.
90. Sheppard DN, Welsh MJ. Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol, 1992, 100, 73-591.
91. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care, 2001, 24, 1706-10.
92. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med, 2002, 19, 221-6.
93. Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol, 2004, 200, 235-44.
94. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med, 2004, 350, 560-9.
95. Rabasa-Lhoret R, Chiasson JL. Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impared glucose tolerance. Drug & Aging, 1998, 13, 131-43.
96. Kentrup H, Bongers H, Spengler M, Kusenbach G, Skopnik H. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Eur J Pediatr, 1999, 158, 455-9.
97. Davidson J. Should postprandial glucose be measured and treated to a particular target? Yes. Diabetes Care, 2003, 26, 1919-21.